News

AgroSpheres Awarded Competitive SBIR Phase II Grant from the National Science Foundation to Combat Fall Armyworm

AgroSpheres, Inc. has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant for $999,653 to progress its R&D collaboration with the University of Tennessee on an RNAi biological insecticide targeting fall armyworm (FAW). Larvae of FAW are one of the most economically devastating insect pests in its native region of the tropical Americas, and is quickly becoming a global superpest threatening food security worldwide. The Phase II award from the NSF represents confidence in results demonstrating efficient RNAi in FAW and the capability of the proprietary technology platform to power in field delivery.

The FAW team at the University of Tennessee Institute of Agriculture is led by Dr. Juan Luis Jurat-Fuentes, a Professor in the Department of Entomology and Plant Pathology with more than a decade of expertise on controlling FAW with insecticidal proteins and developing RNAi against this pest. The team is enthusiastic to continue its exciting collaboration with AgroSpheres. “We are looking forward to applying our expertise on fall armyworm to further test AgroSpheres’ novel AgriCell RNAi production and delivery method to control this important crop pest,” Dr. Jurat-Fuentes says. He adds, “We have seen unprecedented RNAi activity against fall armyworm through testing the AgriCell platform in replicated lab trials and are excited to continue to the greenhouse and the field.”

“We are motivated by the vote of confidence from the NSF to develop the next generation of crop protection products, ” said Ameer Shakeel, Founder and Chief Technology Officer at AgroSpheres. “We believe we have a transformative technology for the cost-effective synthesis and delivery of RNA which has been further enhanced by integrating Orion’s Motif Fingerprinting.”

The NSF SBIR Phase II grant follows two recent grant awards to AgroSpheres. The first is from the Center for Innovative Technology’s inaugural Commonwealth Commercialization Fund (CCF) for $100,000 to support AgroSpheres’ commercial efforts. The second is from the USDA SBIR Phase I program $100,000 to fund the replacement of microplastics and petroleums in pesticide formulations. AgroSpheres is grateful for the support of the state and federal institutions.

 

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business